Atreca (NASDAQ:BCEL) reported quarterly losses of $(0.72) per share. This is unchanged from the same period last year.
Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful
Soleno Therapeutics Inc (NASDAQ:SLNO) provided an update following recent communications with the FDA regarding the development of once-daily DCCR (diazoxide choline)…